Left Atrial Appendage Closure: Effective to Reduce Risk of Stroke?

Original Title: Effectiveness of Left Atrial Appendage Exclusion Procedures to Reduce the Risk of Stroke: A Systematic Review of the Evidence.

Reference: North Noelck et al. Circ Cardiovasc Qual Outcomes. July 2016. Published ahead of print.

 
Left Atrial Appendage ClosureAtrial fibrillation is an important cause of stroke. Oral anticoagulation reduces the risk of stroke but, on the other hand, increases the risk of bleeding. Left atrial appendage closure procedures have been designed to isolate the left atrial appendage (LAA) from blood circulation and is an alternative to oral anticoagulation.

This study is a systematic review to assess the risks and benefits of percutaneous or surgical LAA closure.

In all, 20 studies met the pre-specified inclusion criteria, from where researchers recovered patient characteristics, and stroke, mortality and adverse events rates.  The quality and state of evidence were also assessed according to publication criteria.

Researchers found studies with low quality evidence concluding LAA closure and anticoagulation had similar risk of stroke and mortality rates, noting, however, this evidence was limited to Watchman implantation in patients eligible for oral anticoagulation at short term.

Observational studies provide stronger evidence on the possibility of periprocedural adverse events after percutaneous LAA closure with practically all available devices.

There is little evidence on surgical LAA closure in the context of heart surgery for another indication (either cardiac or vascular), but it doesn’t seem to contribute to surgery-related adverse events that. There is insufficient data to argue that surgery will reduce stroke risk.

 

Conclusion

There is limited evidence to support the Watchman might be superior to long term oral anticoagulation in selected patients. There is not enough data on the effectiveness of different devices in patients who are ineligible for oral anticoagulation. Percutaneous LAA closure is associated with a relatively high risk of periprocedural complications.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....